FDA approves first gene therapy – tisagenlecleucel for ALLAugust 30, 2017Hematologic MalignanciesImmuno-oncology
The Challenges of Precision Medicine and New Advances in Molecular Diagnostic Testing in Hematolymphoid Malignancies: Impact on the VHA (FULL)August 4, 2017Hematologic MalignanciesImmuno-oncology
Avelumab induces response in Hodgkin lymphoma after failed allo-SCTJuly 20, 2017Immuno-oncologyHematologic Malignancies
Six Open Clinical Trials That Are Expanding Our Understanding of ImmunotherapiesNovember 15, 2016Immuno-oncology
Pembrolizumab ‘new standard of care’ in advanced PD-L1-rich NSCLCOctober 17, 2016Lung CancerImmuno-oncology
Pembrolizumab boosts response but not survival in small study of advanced NSCLCOctober 13, 2016Lung CancerImmuno-oncology
Glimmer of promise for nivolumab in neoadjuvant NSCLC therapyOctober 7, 2016Lung CancerImmuno-oncology
10 recommendations for the Cancer MoonshotSeptember 9, 2016Health PolicyAMLImmuno-oncologyBusiness of Medicine
